ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
75 announcements with these filters
CRISIL Ratings has continued the ratings on Anupam Rasayan India Ltd's bank facilities and non-convertible debentures, maintaining the 'Rating Watch with Developing Implications'.
Promoter Anand Sureshbhai Desai created a pledge on 2,00,000 equity shares of Anupam Rasayan India Limited to secure debt aggregating to ₹160 Crore.
Anupam Rasayan started FY27 with 36% revenue growth, primarily driven by the Jehoshaphat (J-Hock) acquisition and new product commercialization in flow chemistry.
Anupam Rasayan reported strong Q1FY27 consolidated revenue of ₹6,675 Mn, up 36% YoY. Strategy focuses on expanding the fluorination and CDMO platforms via strategic acquisitions of Jayhawk and Bliss GVS Pharma.
Anupam Rasayan India Ltd reported Q1 FY27 revenue of ₹667.5 Crore, a 36% YoY increase. The company signed a ₹2,850 Crore LOI with BASQUEVOLT for specialty chemicals.
Anupam Rasayan India Limited has appointed Mr. Ravi Desai as Chief Operating Officer effective August 14, 2026. He previously served as the company's Sales Head.
Anupam Rasayan India Ltd reported revenue from operations of ₹655 Cr (+34.8% YoY) and net profit of ₹51.2 Cr (+5.6% YoY) for Q1 FY27.
Anupam Rasayan India Limited has allotted equity shares under its Employee Stock Option (ESOP) scheme. This allotment increases the company's total paid-up share capital.
Anupam Rasayan allotted 1,531 equity shares under its ESOP Scheme 2020 to eligible employees. The total exercise realization for this allotment is ₹0.03 Crore.
Anupam Rasayan India Ltd scheduled a board meeting on August 14, 2026, to consider and approve its unaudited financial results for the quarter ended June 30, 2026.
Anupam Rasayan India Ltd filed the Letter of Offer for its open offer to acquire a 26% stake in Bliss GVS Pharma Ltd for ₹829.03 Crore.
Anupam Rasayan India Ltd filed its quarterly shareholding pattern as of June 30, 2026. The report details equity distribution among promoters and public shareholders.
Anupam Rasayan completed the 100% acquisition of Mates Visa Consultancy for INR 0.001 Crore. The target will support a restructuring exercise involving Bliss GVS Pharma.
Anupam Rasayan signed a ₹2,886.66 Crore Letter of Intent with Spain's Basquevolt. The 10-year agreement involves supplying specialty chemicals for battery applications.
Anupam Rasayan signed an LOI with Basquevolt for specialty chemical supplies worth $300 Million (Rs. 2,880 Crore). The contract spans a 10-year period.
Anupam Rasayan commercialised ETFA using flow chemistry, a world-first. This strengthens its specialty chemicals portfolio and global market position.
Anupam Rasayan announced a ₹829.03 Crore open offer to acquire a 26% stake in Bliss GVS Pharma Limited. The move follows a majority stake acquisition via SPA.
Anupam Rasayan scheduled a plant visit for several institutional investors on June 9, 2026. The visit at Jhagadia GIDC involves analysts from Prabhudas Liladhar and Marcellus.
Q4FY25 saw 31% QoQ consolidated revenue growth. Full year FY25 consolidated revenue was ₹14,485 Mn, a 4% YoY degrowth, reflecting H1 macro weakness recovered in H2.
India Ratings and Research updated Anupam Rasayan's credit rating to 'IND AA-' with Negative Implications. Ratings cover bank loans and NCDs, reflecting current creditworthiness assessments.
CRISIL assigned 'Crisil A+' to Anupam Rasayan's ₹160 Crore NCDs and placed ₹1,620 Crore bank facilities on rating watch. This follows the acquisition of Bliss GVS Pharma.
Anupam Rasayan promoter Anand Sureshbhai Desai pledged 31,50,000 shares to secure ₹160 Crore in non-convertible debentures. This transaction increases total promoter encumbrances to 6.13%.
Anupam Rasayan delivered record FY26 revenue of ₹2,384cr, up 65% YoY, driven by acquisitions and diversification into Pharma and Fluorination.
Anupam Rasayan India Ltd submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report confirms overall regulatory compliance with no material deviations.
Anupam Rasayan allotted ₹160 Crore of secured non-convertible debentures to Aditya Birla Capital. The unlisted 10.25% coupon instruments carry a 13-month tenure for debt repayment.
Anupam Rasayan delivered record FY26 revenue of ₹2,384cr, driven by aggressive acquisitions (J-Hock, Bliss GVS) and a pivot from agrochemicals to high-margin pharma and polymer segments.
Anupam Rasayan will acquire a controlling 43.30% stake in Bliss GVS Pharma for ₹1369.51 Crore. This strategic acquisition integrates pharmaceutical operations and unlocks operational synergies.
Anupam Rasayan recommended a final dividend of ₹1.5 per equity share for FY 2025-26. This 15% payout rewards shareholders, though the record date remains pending.
Anupam Rasayan announced the acquisition of Bliss GVS Pharma (43.3-48.2% stake plus open offer) to expand into pharmaceutical formulations and regulated markets like the USA.
Anupam Rasayan reported record FY26 consolidated revenue of ₹23,836 Mn (up 65% YoY) and PAT of ₹2,222 Mn (up 39% YoY). Strategy focuses on backward integration via Tanfac and US expansion through Jayhawk acquisition.